Eyetech Pharmaceuticals Report issue

Contributed to NME For profit Phase 4
Founded: New York NY United States (1997)
Status: Acquired by Bausch Health Companies (2012)

Organization Overview

First Clinical Trial
2001
NCT00321997
First Marketed Drug
2004
pegaptanib (macugen)
First NDA Approval
2004
pegaptanib (macugen)
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (1)

pegaptanib (macugen) (2004 NDA)

Drugs in Phase 4 Trials (2)

pegaptanib (macugen) (14 trials)

verteporfin (visudyne) (1 trial)

Indications

Approved Indications


 

Macular Degeneration

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 2)

Choroidal Neovascularization (Phase 3)

Edema (Phase 2)

Macular Degeneration (Phase 4)

Macular Edema (Phase 4)

Neovascularization, Pathologic (Phase 3)

Retinal Vein Occlusion (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 2